Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 377

Similar articles for PubMed (Select 18953436)

1.

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.

Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA.

Neoplasia. 2008 Nov;10(11):1268-74.

2.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

3.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

4.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
5.

The p53 pathway and its inactivation in neuroblastoma.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):93-8. Review.

PMID:
12880966
6.

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.

Petroni M, Veschi V, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, Dominici C, McDowell HP, Rinaldi C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Soddu S, Giannini G.

Mol Cancer Res. 2011 Jan;9(1):67-77. doi: 10.1158/1541-7786.MCR-10-0227. Epub 2010 Dec 20.

7.

MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.

Cancer Res. 2007 Mar 15;67(6):2448-55.

8.

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

Cancer Res. 2010 Feb 15;70(4):1377-88. doi: 10.1158/0008-5472.CAN-09-2598. Epub 2010 Feb 9.

10.

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.

Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J, Tweddle DA.

Cell Cycle. 2006 Nov;5(22):2639-47. Epub 2006 Nov 15.

PMID:
17172827
11.

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. Epub 2005 Jan 11.

12.

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73. doi: 10.1073/pnas.0901418106. Epub 2009 Jun 12.

13.

Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.

Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F.

Carcinogenesis. 2008 Oct;29(10):1869-77. doi: 10.1093/carcin/bgn147. Epub 2008 Jun 19.

14.

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP.

Cancer Res. 2001 Aug 15;61(16):6185-93.

15.

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.

Cell Cycle. 2011 Nov 1;10(21):3778-87. doi: 10.4161/cc.10.21.17973. Epub 2011 Nov 1.

PMID:
22052359
16.
17.

Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling.

Albihn A, Mo H, Yang Y, Henriksson M.

Int J Cancer. 2007 Oct 15;121(8):1821-9.

PMID:
17565738
18.

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.

Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P.

Oncogene. 2008 May 1;27(20):2910-22. Epub 2007 Nov 19.

PMID:
18026138
19.

Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.

Yang B, Reynolds CP.

Clin Cancer Res. 2005 Apr 1;11(7):2774-80.

20.

Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD.

BMC Cancer. 2006 Jul 5;6:177.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk